Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

NCT02673814 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: durvalumab
BIOLOGICAL: bavituximab

Sponsor

Peregrine Pharmaceuticals